Karl-Heinz Baringhaus
Site Director R&D Frankfurt, Sanofi
Grasping opportunities for better drug discovery: Interdisciplinarity, deeper insights into disease, new technologies and better decision-making
Karl-Heinz addresses challenges of interdisciplinary integration, such as complex decisions across diverse disciplines, high volume of biological data, and more. He brings examples from the industry to improve interdisciplinary collaboration by streamlining drug discovery, insights, decision filing and automation.
Karl-Heinz Baringhaus obtained his Ph.D. in synthetic organic chemistry at the University of Münster. After a postdoctoral fellowship at Stanford University he joined Hoechst AG in 1990 where he was working six years in Medicinal Chemistry. He then moved into Molecular Modeling and in 2000 became Head of Computational Chemistry at Aventis Pharma. From 2005 to 2010 he was Director of Drug Design at Sanofi-Aventis Pharma Deutschland GmbH. In 2010 he was promoted to Head of Structure, Design & Informatics consisting of Computational Biology & Bioinformatics, Computer-aided Drug Design, Scientific Computing & Data Management as well as Structural Biology. Since 2012, Karl-Heinz has been R&D Site Director in Frankfurt.
Talks you might be also interested in
Nessa Carson
AstraZeneca
How not to waste a chemist's time: Chemical insights through great user experience
Adrian Stevens
Chemaxon
Developing new science and technologies that aid future drug discovery needs
Peter Ertl
Formerly of Novartis
The magic rings: Navigation in the ring chemical space guided by the bioactive rings